Policy & Regulation
HitGen signs research collaboration with Takeda Pharmaceutical
13 September 2017 -

China-based HitGen has signed a research collaboration with Japan-based Takeda Pharmaceutical Company.

It was reported yesterday that the collaboration is aimed at discovering novel small molecule leads for multiple targets in Takeda's therapeutic areas of interest.

Under the contract, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively to Takeda. Under the terms of the agreement, HitGen will receive upfront compensation, and be eligible for milestone payments from Takeda. Specific financial details were not revealed.